Citation Impact
Citing Papers
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
2006
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
2016
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Pharmaceutical Particle Engineering via Spray Drying
2007 Standout
Social determinants of dietary habits in Denmark
2001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
2013
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
2022
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
2008
Risk factors for more severe regional musculoskeletal symptoms: A two‐year prospective study of a general working population
2007 Standout
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
2014 Standout
Does social class predict diet quality?
2008 Standout
The Changing Organization of Work and the Safety and Health of Working People: A Commentary
2003
The Copenhagen Psychosocial Questionnaire—a tool for the assessment and improvement of the psychosocial work environment
2005 Standout
Sustained-release self-dissolving micropiles for percutaneous absorption of insulin in mice
2007
Type 2 diabetes
2017 Standout
A case–control study relating railroad worker mortality to diesel exhaust exposure using a threshold regression model
2008
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
2017 Standout
Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering
2011
Type 1 diabetes
2013 Standout
Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines
2009
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials
2015
Pharmacology of Insulin Detemir
2007
A review of human and analogue insulin trials
2006
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2021
Insulin detemir: from concept to clinical experience
2006
Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes
2004
Microneedles for drug and vaccine delivery
2012 Standout
Type 2 diabetes mellitus
2015 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
2012
Leadership styles and outcome patterns for the nursing workforce and work environment: A systematic review
2018 Standout
Global health status: two steps forward, one step back
2000
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
2019 Standout
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
2021
Leadership styles and outcome patterns for the nursing workforce and work environment: A systematic review
2009 Standout
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
2017
New Insulins and New Aspects in Insulin Delivery
2015
The Copenhagen Burnout Inventory: A new tool for the assessment of burnout
2005 Standout
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
2007
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes
2006
Globalization, food and health in Pacific Island countries.
2005 Standout
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
2021
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
2016
New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
2016
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Remaining useful life estimation – A review on the statistical data driven approaches
2010 Standout
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
2011
Diabetes and Cancer
2010 Standout
Research confuses me: what is the difference between case-control and cohort studies in quantitative research?
2013 Standout
Pathophysiology of Type 2 Diabetes Mellitus
2020 Standout
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
2017
“Friday off”: Reducing Working Hours in Europe
2013 Standout
Socioeconomic status and psychosocial work environment: results from a Danish national study
2002
Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes
2008
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
2014
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy)
2016
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
2016
Global Burden of Cardiovascular Diseases
2001 Standout
Perfluoroalkyl Chains Direct Novel Self-Assembly of Insulin
2011
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
2014
Pushing the mass limit for intact launch and photoionization of large neutral biopolymers
2018 StandoutNobel
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
2018
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
2006 Standout
Works of Lars Endahl being referenced
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
2011
Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis
1996
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
2012
Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes
2006
Increasing inequality in ischaemic heart disease morbidity among employed men in Denmark 1981-1993: the need for a new preventive policy
1999
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
2021
Time‐action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups*
2006
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials
2012
Insulin detemir under steady‐state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes
2006
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
2012
Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
2004
Insulin Degludec in Type 1 Diabetes
2011
A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
2005